Synthesis of new building blocks for boron-rich oligomers in boron neutron capture therapy (BNCT). I

Recent Advances in the Synthesis of High Boron-Loaded Nucleic Acids for BNCT

Boron clusters attract considerable attention as promising therapeutic tools for boron neutron capture therapy (BNCT). They combine high boron content with high chemical and biological stability, biorthogonality, and low toxicity. The development of oligonucleotide-based constructs and nucleic acid-like molecules, such as oligomeric phosphate diesters, bearing one or multiple boron clusters permits to create potential high boron-loaded agents for BNCT with good bioavailability, specifically interacting with nucleic acids inside the cell. Here, we shortly review the strategies and solutions in the design of oligonucleotide conjugates with boron clusters in light of the requirements for effective BNCT and future prospects of their practical use.

Synthesis and evaluation of carbaborane derivatives of indomethacin as cyclooxygenase inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological activities by inhibiting cyclooxygenase (COX)-1 and COX-2. Previous studies have shown that esters and amides of non-selective inhibitors such as indomethacin are selective against COX-2, which is the therapeutically relevant isoform. Structure-activity analysis indicates that substituted phenyl rings are tolerated as ester components. In the present study, the introduction of inorganic ortho- and meta-carbaborane moieties was explored with the aim to create COX-2 inhibitors and more importantly to investigate the validity of using these boron clusters as drug entities. Interestingly, only the ortho-carbaborane ester was active whereas the meta isomer was not. A similar lack of inhibitory potency was observed when an adamantyl substituent or alkylene spacers at the carbaborane were introduced in the ester functionality.

Mono- and Di-nuclear Gold(I) Complexes Containing 1,12-Dicarba-closo-dodecaborane(12)

The first examples of gold(i) complexes containing monodentate diphenylphosphine-1,12-carborane and bidentate 1,12-bis(diphenylphosphine)-1,12-carborane ligands are reported.

Coupling of Amino Carboranes to Carboxylic Acid Containing Substrates

The reactivity of the known amino carboranes 1-H(2)NCH(2)-1,2-C(2)B(10)H(11) and 7-H(3)N-7-CB(10)H(12) with carboxylic acid containing substrates was investigated. The reactions studied using the coupling reagent, 1,1'-carbonyldiimidazole, resulted in the preparation of a series of amides in moderate to high yield. The relative importance of this type of research resides in the fact that it allows the introduction of amino acids in close contact with the carborane cage. These compounds can constitute a new generation of substrates useful in boron neutron capture therapy. Our emphasis lies in the development of suitable synthetic schemes allowing the preparation of this type of compound. Experimental details and analytical data supporting the formulation of the prepared compounds are reported.

Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization

The application of immunoprotein-based targeting strategies to the boron neutron-capture therapy of cancer poses an exceptional challenge, because viable boron neutron-capture therapy by this method will require the efficient delivery of 10(3) boron-10 atoms by each antigen-binding protein. Our recent investigations in this area have been focused on the development of efficient methods for the assembly of homogeneous immunoprotein conjugates containing the requisite boron load. In this regard, engineered immunoproteins fitted with unique, exposed cysteine residues provide attractive vehicles for site-specific modification. Additionally, homogeneous oligomeric boron-rich phosphodiesters (oligophosphates) have been identified as promising conjugation reagents. The coupling of two such boron-rich oligophosphates to sulfhydryls introduced to the CH2 domain of a chimeric IgG3 has been demonstrated. The resulting boron-rich immunoconjugates are formed efficiently, are readily purified, and have promising in vitro and in vivo characteristics. Encouragingly, these studies showed subtle differences in the properties of the conjugates derived from the two oligophosphate molecules studied, providing a basis for the application of rational design to future work. Such subtle details would not have been as readily discernible in heterogeneous conjugates, thus validating the rigorous experimental design employed here.